"Carcinoma in Situ" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
| Descriptor ID |
D002278
|
| MeSH Number(s) |
C04.557.470.200.240
|
| Concept/Terms |
Carcinoma in Situ- Carcinoma in Situ
- Carcinoma, Preinvasive
- Preinvasive Carcinoma
- Carcinoma, Intraepithelial
- Intraepithelial Carcinoma
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma in Situ".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma in Situ".
This graph shows the total number of publications written about "Carcinoma in Situ" by people in this website by year, and whether "Carcinoma in Situ" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 3 | 1 | 4 |
| 1996 | 7 | 3 | 10 |
| 1997 | 5 | 3 | 8 |
| 1998 | 1 | 1 | 2 |
| 1999 | 6 | 3 | 9 |
| 2000 | 2 | 4 | 6 |
| 2001 | 8 | 6 | 14 |
| 2002 | 11 | 4 | 15 |
| 2003 | 5 | 1 | 6 |
| 2004 | 4 | 4 | 8 |
| 2005 | 8 | 2 | 10 |
| 2006 | 9 | 6 | 15 |
| 2007 | 7 | 1 | 8 |
| 2008 | 7 | 5 | 12 |
| 2009 | 5 | 3 | 8 |
| 2010 | 15 | 4 | 19 |
| 2011 | 12 | 2 | 14 |
| 2012 | 14 | 1 | 15 |
| 2013 | 9 | 3 | 12 |
| 2014 | 9 | 4 | 13 |
| 2015 | 7 | 1 | 8 |
| 2016 | 8 | 2 | 10 |
| 2017 | 4 | 1 | 5 |
| 2018 | 7 | 1 | 8 |
| 2019 | 2 | 2 | 4 |
| 2020 | 6 | 1 | 7 |
| 2021 | 6 | 0 | 6 |
| 2022 | 9 | 0 | 9 |
| 2023 | 5 | 0 | 5 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma in Situ" by people in Profiles.
-
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug; 30(8):2216-2223.
-
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun; 25(6):720-730.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.
-
HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024 Mar 01; 43(2):134-139.
-
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024 Jan 01; 48(1):e11-e23.
-
Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia. J Clin Invest. 2023 06 15; 133(12).
-
A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study. Cancer Epidemiol Biomarkers Prev. 2022 12 05; 31(12):2185-2191.
-
HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases. Int J Gynecol Pathol. 2023 Jul 01; 42(4):338-346.